leisure time -WSS

leisure time

author：explore 2025-09-30 18:54:34 - browse：51

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： The FDA weighs the risks of candy

WSS

CDC recommends rationing of RSV shot due to shortages

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The battle over 'scope creep' and who gets to be called 'doctor'

First Opinion Podcast: How to protect health care in times of war

A new crop of companies is reshaping the health data economy

Chimpanzees, like humans and whales, get menopause: Study

focus

leisure time

focus

Affirmative action in medical school literally saved lives

Dems pitch expanding Medicare power to negotiate drug prices

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why Sanofi got shellacked over its spinoff

23andMe had bad news about my health. I wish a person had delivered it

Biden's order seeks to regulate AI risk without stifling innovation

As demand for Covid shots wanes, Moderna seeks its next success

Meta's Zuckerberg and Chan on track to put $50 billion into science

New air purifier tech could be key to improving indoor air quality

Chimpanzees, like humans and whales, get menopause: Study

leisure time

The haunting brain science of long Covid

Will the FTC rein in IQVIA's health data empire?

New Alzheimer's drugs heat up race for early detection blood tests

Rise in cancer among younger people worries and puzzles doctors

The haunting brain science of long Covid

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

entertainment

hotspot

focus

knowledge